186 related articles for article (PubMed ID: 3768240)
1. Relationship between alpha 1-acid glycoprotein and distribution of disopyramide and mono-N-dealkyldisopyramide in whole blood.
Bredesen JE; Kierulf P
Br J Clin Pharmacol; 1986 Sep; 22(3):281-6. PubMed ID: 3768240
[TBL] [Abstract][Full Text] [Related]
2. Relationship between alpha 1-acid glycoprotein and plasma binding of disopyramide and mono-N-dealkyldisopyramide.
Bredesen JE; Kierulf P
Br J Clin Pharmacol; 1984 Nov; 18(5):779-84. PubMed ID: 6508986
[TBL] [Abstract][Full Text] [Related]
3. Plasma binding of disopyramide and mono-N-dealkyldisopyramide.
Bredesen JE; Pike E; Lunde PK
Br J Clin Pharmacol; 1982 Nov; 14(5):673-6. PubMed ID: 7138747
[TBL] [Abstract][Full Text] [Related]
4. A simple method for the simulation of unbound serum disopyramide concentration in patients.
Kishino S; Kohri N; Iseki K; Miyazaki K; Nomura A; Yasuda H
J Pharmacobiodyn; 1991 Sep; 14(9):493-9. PubMed ID: 1779403
[TBL] [Abstract][Full Text] [Related]
5. [Accumulation of a disopyramide metabolite in renal failure].
Otsu T; Ito T; Inagaki Y; Amano I; Masamoto S; Niwa M
Nihon Jinzo Gakkai Shi; 1993 Sep; 35(9):1065-71. PubMed ID: 8230817
[TBL] [Abstract][Full Text] [Related]
6. Effects of serum concentrations of disopyramide and its metabolite mono-N-dealkyldisopyramide on the anticholinergic side effects associated with disopyramide.
Tsuchishita Y; Fukumoto K; Kusumoto M; Ueno K
Biol Pharm Bull; 2008 Jul; 31(7):1368-70. PubMed ID: 18591776
[TBL] [Abstract][Full Text] [Related]
7. Protein binding of disopyramide--displacement by mono-N-dealkyldisopyramide and variation with source of alpha-1-acid glycoprotein.
Haughey DB; Steinberg I; Lee MH
J Pharm Pharmacol; 1985 Apr; 37(4):285-8. PubMed ID: 2860235
[TBL] [Abstract][Full Text] [Related]
8. Accumulation of a disopyramide metabolite in renal failure.
Inagaki Y; Amano I; Otsu T
ASAIO J; 1993; 39(3):M609-13. PubMed ID: 8268610
[TBL] [Abstract][Full Text] [Related]
9. Changes in the binding capacity of alpha-1-acid glycoprotein in patients with renal insufficiency.
Kishino S; Nomura A; Di ZS; Sugawara M; Iseki K; Kakinoki S; Kitabatake A; Miyazaki K
Ther Drug Monit; 1995 Oct; 17(5):449-53. PubMed ID: 8585106
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous determination of disopyramide and its mono-N-dealkylated metabolite enantiomers in human plasma and urine by enantioselective high-performance liquid chromatography.
Takahashi H; Tamura A; Ogata H; Masuhara K
J Chromatogr; 1990 Aug; 529(2):347-58. PubMed ID: 2229254
[TBL] [Abstract][Full Text] [Related]
11. Nomogram for estimating plasma unbound disopyramide concentrations in patients with varying plasma alpha 1-acid glycoprotein concentrations.
Echizen H; Ishikawa S; Koike K; Ishizaki T
Ther Drug Monit; 1995 Apr; 17(2):145-52. PubMed ID: 7624903
[TBL] [Abstract][Full Text] [Related]
12. Protein binding of disopyramide and elevated alpha-1-acid glycoprotein concentrations in serum obtained from dialysis patients and renal transplant recipients.
Haughey DB; Kraft CJ; Matzke GR; Keane WF; Halstenson CE
Am J Nephrol; 1985; 5(1):35-9. PubMed ID: 3881959
[TBL] [Abstract][Full Text] [Related]
13. Plasma concentrations and protein binding of disopyramide and mono-N-dealkyldisopyramide during chronic oral disopyramide therapy.
Aitio ML
Br J Clin Pharmacol; 1981 Apr; 11(4):369-75. PubMed ID: 7259930
[TBL] [Abstract][Full Text] [Related]
14. Stereoselective metabolism and pharmacokinetics of disopyramide enantiomers in humans.
Le Corre P; Gibassier D; Sado P; Le Verge R
Drug Metab Dispos; 1988; 16(6):858-64. PubMed ID: 2907466
[TBL] [Abstract][Full Text] [Related]
15. Age- and gender-related differences in carbohydrate concentrations of alpha1-acid glycoprotein variants and the effects of glycoforms on their drug-binding capacities.
Kishino S; Nomura A; Itoh S; Nakagawa T; Takekuma Y; Sugawara M; Furukawa H; Todo S; Miyazaki K
Eur J Clin Pharmacol; 2002 Dec; 58(9):621-8. PubMed ID: 12483455
[TBL] [Abstract][Full Text] [Related]
16. Prolonged variability in plasma protein binding of disopyramide after acute myocardial infarction.
David BM; Ilett KF; Whitford EG; Stenhouse NS
Br J Clin Pharmacol; 1983 Apr; 15(4):435-41. PubMed ID: 6849779
[TBL] [Abstract][Full Text] [Related]
17. The acute changes in serum binding of disopyramide and flecainide after myocardial infarction.
Caplin JL; Johnston A; Hamer J; Camm AJ
Eur J Clin Pharmacol; 1985; 28(3):253-5. PubMed ID: 4007029
[TBL] [Abstract][Full Text] [Related]
18. Stereoselective disposition and metabolism of disopyramide in pediatric patients.
Echizen H; Takahashi H; Nakamura H; Ochiai K; Chiba K; Koike K; Ogata H; Ishizaki T
J Pharmacol Exp Ther; 1991 Dec; 259(3):953-60. PubMed ID: 1762088
[TBL] [Abstract][Full Text] [Related]
19. Alpha-1-acid glycoprotein concentration and the protein binding of disopyramide in healthy subjects.
Kishino S; Nomura A; Di ZS; Sugawara M; Iseki K; Kakinoki S; Kitabatake A; Miyazaki K
J Clin Pharmacol; 1995 May; 35(5):510-4. PubMed ID: 7657852
[TBL] [Abstract][Full Text] [Related]
20. Binding characteristics of KNI-272 to plasma proteins, a new potent tripeptide HIV protease inhibitor.
Kiriyama A; Nishiura T; Ishino M; Yamamoto Y; Ogita I; Kiso Y; Takada K
Biopharm Drug Dispos; 1996 Dec; 17(9):739-51. PubMed ID: 8968527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
